Find the Perfect Plan for Your Investment Journey
Last Price
52 Week Range
$17.86 - $58.40
Next Earnings Date
May 09 2025
Next Earnings Date
May 09 2025
Last Price
Market Cap | $3.43B |
EV | $2.67B |
Shares Outstanding | 82.90M |
Beta | -0.18 |
Analyst Rating | BUY |
Analyst Target Price | $77.64 |
P/E 2025E | - |
P/Revenue 2025E | - |
Revenue | - |
EPS | -9.10% |
Operating Cash Flow | -42.50% |
Free Cash Flow | -42.40% |
Revenue | - |
EPS | -7.20% |
Operating Cash Flow | -9.70% |
Free Cash Flow | -12.60% |
Gross Margin 2025E | - |
Net Profit Margin 2025E | - |
ROE 2025E | -43.63% |
ROCE 2024 | -39.22% |
DPS 2025E | $0.00 |
Payout Ratio 2025E | 0.00% |
Div. Yield 2025E | 0.00% |
DPS Last 3Y CAGR | - |
Price
%
1M
3M
6M
1Y
3Y
5Y
Akero Therapeutics, Inc.
AKRO
Sector
Healthcare
Industry
Biotechnology
CEO
Cheng, Andrew
Employees
63
Website
akerotx.comIPO Date
2019-06-20
Headquarters
601 Gateway Boulevard, Suite 350, South San Francisco, California, 94080, United States
COMPANY
NEWSLETTER
© Copyright 2025, All Rights Reserved